Arrowhead Pharmaceuticals (ARWR) Financials: History & Chart

Arrowhead Pharmaceuticals, Inc.(ARWR)

Biotechnology · Pasadena, CA

$62.03-0.32 (-0.51%)

Delayed quote: Oct 6, 2026, 2:00 PM EDT

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.

Pasadena, CA

711 employees

arrowheadpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Christopher R. Anzalone

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	669.50M	75.25M	73.74M	264.03M	256.47M	27.77M	542.71M	2.50M	0.00
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.03M
Gross Profit	669.50M	75.25M	73.74M	264.03M	256.47M	27.77M	542.71M	2.50M	-5.03M
Gross Profit Margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	N/A
Total Operating Expenses	895.93M	245.35M	215.00M	223.22M	212.37M	193.32M	161.51M	163.91M	157.18M
Research & Development	723.37M	198.22M	173.25M	177.20M	174.69M	162.37M	133.10M	137.00M	131.39M
Selling, General & Administrative	171.06M	47.12M	41.24M	45.52M	37.18M	30.44M	27.89M	26.40M	25.79M
Operating Income (EBIT)	-226.44M	-170.09M	-141.26M	40.81M	44.11M	-165.55M	381.20M	-161.41M	-162.20M
Operating Margin	-33.8%	-226.0%	-191.6%	15.5%	17.2%	-596.2%	70.2%	-6456.5%	N/A
Income Before Tax (EBT)	-252.08M	-178.91M	-137.56M	28.27M	36.12M	-179.09M	369.62M	-175.12M	-172.80M
Interest Income	52.55M	16.93M	16.87M	9.69M	9.05M	11.02M	9.62M	7.60M	7.17M
Interest Expense	92.61M	24.56M	23.85M	22.50M	21.69M	24.38M	21.64M	21.65M	14.65M
Other Income/Expense	-25.64M	-8.81M	3.69M	-12.54M	-7.99M	-13.54M	-11.59M	-13.70M	-10.60M
Net Income	-319.95M	-194.28M	-132.73M	30.81M	-23.75M	-175.24M	370.44M	-173.09M	-170.54M
Income Tax Expense	20.05M	11K	7K	29K	20.00M	-437K	1.75M	103K	546K
Net Profit Margin	-47.8%	-258.2%	-180.0%	11.7%	-9.3%	-631.1%	68.3%	-6923.4%	N/A
EBITDA	-201.29M	-164.09M	-134.89M	47.20M	50.49M	-159.33M	387.29M	-156.18M	-157.18M
EBITDA Margin	-30.1%	-218.1%	-182.9%	17.9%	19.7%	-573.8%	71.4%	-6247.1%	N/A
Depreciation & Amortization	25.15M	6.00M	6.37M	6.39M	6.39M	6.22M	6.08M	5.24M	5.03M
EPS Basic	-2.24	-1.36	-0.93	0.22	-0.17	-1.26	2.78	-1.39	-1.40
EPS Diluted	-2.24	-1.36	-0.93	0.22	-0.17	-1.26	2.75	-1.39	-1.40
Weighted Average Basic Shares	143.38M	143.38M	142.42M	140.05M	135.70M	139.04M	133.36M	124.85M	121.99M
Weighted Average Diluted Shares	143.38M	143.38M	142.42M	140.71M	135.70M	139.04M	134.48M	124.85M	121.99M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	09/30/2025	09/30/2024	09/30/2023	09/30/2022	09/30/2021	09/30/2020	09/30/2019	09/30/2018
Revenue	829.45M	3.55M	240.74M	243.23M	138.29M	87.99M	168.80M	16.14M
Cost of Goods Sold	0.00	18.59M	12.49M	10.42M	0.00	0.00	0.00	0.00
Gross Profit	829.45M	-15.04M	228.24M	232.81M	138.29M	0.00	0.00	0.00
Gross Profit Margin	100.0%	-423.7%	94.8%	95.7%	100.0%	0.0%	0.0%	0.0%
Total Operating Expenses	731.10M	586.04M	433.24M	411.32M	287.32M	175.21M	103.17M	67.38M
Research & Development	607.16M	489.22M	342.31M	288.50M	206.34M	123.54M	76.63M	48.30M
Selling, General & Administrative	121.92M	96.82M	90.93M	124.43M	80.98M	52.28M	26.54M	19.08M
Operating Income (EBIT)	98.35M	-601.08M	-205.00M	-178.51M	-149.04M	-93.16M	61.19M	-55.94M
Operating Margin	11.9%	-16927.1%	-85.2%	-73.4%	-107.8%	-105.9%	36.3%	-346.5%
Income Before Tax (EBT)	51.53M	-612.46M	-206.49M	-172.71M	-140.85M	-84.55M	68.15M	-54.45M
Interest Income	37.29M	22.72M	15.30M	5.03M	6.12M	9.19M	6.96M	1.05M
Interest Expense	89.36M	32.35M	18.33M	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	-46.81M	-11.38M	-1.49M	5.80M	8.19M	8.61M	6.96M	1.49M
Net Income	-1.63M	-599.49M	-205.28M	-176.06M	-140.85M	-84.55M	67.97M	-54.45M
Income Tax Expense	21.42M	-2.77M	2.78M	3.79M	2K	2K	174K	2K
Net Profit Margin	-0.2%	-16882.4%	-85.3%	-72.4%	-101.9%	-96.1%	40.3%	-337.3%
EBITDA	122.27M	-582.49M	-192.51M	-168.09M	-140.77M	-87.22M	65.63M	-51.24M
EBITDA Margin	14.7%	-16403.4%	-80.0%	-69.1%	-101.8%	-99.1%	38.9%	-317.4%
Depreciation & Amortization	23.93M	18.59M	12.49M	10.42M	8.27M	5.94M	4.44M	4.70M
EPS Basic	-0.01	-5.00	-1.92	-1.67	-1.36	-0.84	0.72	-0.65
EPS Diluted	-0.01	-5.00	-1.92	-1.67	-1.36	-0.84	0.69	-0.65
Weighted Average Basic Shares	133.76M	119.78M	106.75M	105.43M	103.75M	100.72M	93.86M	83.64M
Weighted Average Diluted Shares	133.76M	119.78M	106.75M	105.43M	103.75M	100.72M	98.61M	83.64M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.